Several of the nation’s largest health insurers rolled out reimbursement policy changes Sept. 1, ranging from new lab testing coverage limits at UnitedHealthcare to a billing overhaul at Blue Cross Blue Shield of Michigan that has drawn pushback from providers, forming a wide-ranging set of payer reimbursement changes September 2026 that providers need to track closely.
UnitedHealthcare’s Lab Testing Policies Within These Payer Reimbursement Changes September 2026
UnitedHealthcare is tightening reimbursement for lab tests across its commercial, Medicare Advantage, exchange, and Medicaid plans. Most commercial, exchange, and MA changes take effect Sept. 1, with Medicaid rollouts staggered by state from August through December. Five new lab testing policies apply: an allergen testing cap of 20 allergens per year for patients 20 and older; a hepatic fibrosis testing restriction to once every six months for hepatitis B, hepatitis C, MASLD, or alcoholic hepatitis patients; non-reimbursement for in vitro chemotherapy sensitivity and resistance assays; a testosterone testing policy excluding asymptomatic individuals; and a vitamin B12 testing limit of once every three months.
UnitedHealthcare’s Genetic Testing Update
The insurer is also updating its genetic testing for neurological disorders policy for individual exchange plans, with revised clinical evidence and applicable codes.
Aetna’s Reimbursement Changes Within This Payer Reimbursement Changes September 2026 Wave
Aetna is making two major changes: expanding its Claim and Code Review Program with new claim edits based on CMS, AMA CPT, and evidence-based guidelines across commercial, Medicare, and student members, and applying a 15% payment reduction to radiology services billed with modifier CT, denoting equipment that doesn’t meet NEMA XR 29-2013 “Smart Dose” standards, aligning with CMS guidelines.
Why the Smart Dose Standard Matters
This reduction targets radiology equipment that lacks specific dose-optimization features, giving providers using older imaging technology a direct financial incentive to upgrade equipment in order to avoid the reduced reimbursement rate on both technical and professional billing components.
BCBS Michigan’s Incident-To Billing Phaseout Within These Payer Reimbursement Changes September 2026
BCBS Michigan is phasing out incident-to billing, a practice under which non-physician providers supervised by a physician were reimbursed at the physician’s higher rate. Starting Sept. 1, enrollment-eligible clinicians still billing incident-to must add modifier SA, and those claims will remain payable at the submitting clinician’s rate but become ineligible for the insurer’s Physician Group Incentive Program and other value-based reimbursement.
A Second Phase Coming in 2027
A second phase takes effect March 1, 2027, when clinicians with their own NPI must bill directly. Those continuing incident-to billing will see reimbursement reduced to 80% of the professional fee schedule, and training-level clinicians, including students, residents, and limited-license social workers, will lose incident-to billing eligibility in office settings entirely.
BCBS Texas and North Carolina Within These Payer Reimbursement Changes September 2026
BCBS Texas is updating 24 lab-related reimbursement policies effective Sept. 4, covering flow cytometry, PSA testing, allergen testing, hepatitis testing, thyroid disease testing, cardiovascular risk assessment, micronutrient testing, drug testing, and colorectal cancer screening.
BCBS North Carolina’s Tiered Surgery Reduction
BCBS North Carolina is changing its multiple and bilateral surgery reimbursement policy effective Sept. 1. For outpatient facility claims, the primary procedure will be reimbursed at 100% of the allowance, the second and third procedures at 50%, and the fourth and subsequent procedures will not be eligible for reimbursement. On the professional side, the schedule changes to 100% for the primary procedure, 50% for the second, and 25% for the third and beyond, applying to all commercial and ASO members.
Molina Healthcare’s Ohio Medicaid Changes Within These Payer Reimbursement Changes September 2026
Molina Healthcare of Ohio is implementing several Medicaid policy changes effective Sept. 1, including a new specialty medication administration site-of-care policy, new clinical coverage criteria for the gene therapy Otarmeni, and revised buy-and-bill pharmacy policies for drugs including Briumvi, Kisunla, Lemtrada, Leqvio, Tysabri and biosimilars, and Tzield. The insurer also revised its duplicate claims payment integrity policy.
Why Specialty Drug Policies Are a Recurring Theme
The prominence of specialty medication and gene therapy coverage changes within Molina’s update reflects a broader industry pattern of insurers tightening site-of-care and buy-and-bill policies specifically for high-cost specialty drugs, an area where reimbursement changes can carry significant financial implications for both providers and patients.
What These Payer Reimbursement Changes September 2026 Mean Going Forward
With six major insurers implementing changes simultaneously this month, providers navigating multiple payer relationships will need to track significantly different lab testing caps, billing modifier requirements, and surgery reimbursement schedules depending on which plans their patient populations use. Given BCBS Michigan’s two-phase incident-to billing phaseout extending into 2027, practices relying heavily on non-physician providers should begin planning now for the more significant reimbursement reduction and eligibility loss the second phase will bring.
What to Watch Going Forward
As these changes take effect, industry observers will likely watch how providers respond to BCBS Michigan’s incident-to billing overhaul specifically, given the pushback it has already generated, and whether other Blue Cross Blue Shield affiliates or national insurers adopt similar restrictions. Given the breadth of lab testing policy changes across UnitedHealthcare, BCBS Texas, and Molina Healthcare simultaneously, this wave of payer reimbursement changes September 2026 may signal a broader, coordinated industry push toward tighter utilization management for diagnostic testing and specialty drug administration heading into the final quarter of the year.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
